9:44   Kalretikulin Mutasyonları ve Primer Miyelofibrozis | Dr. Gonca Gülbay 1:36   MYELOFİBROSİZ HASTASI ADNAN ÇOKLUK, İLİK NAKLİ BEKLİYOR 2:42   The COMFORT-I and COMFORT-II Trials in Myelofibrosis 1:20   The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies 1:30   The safety profile of imetelstat in myeloid malignancies 2:21   Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits 4:39   Imetelstat shows promise in advanced myelofibrosis 3:17   Ziftomenib: mechanism of action and promising results in patients with KMT2Ar or NPM1m AML 9:46   Primary (idiopathic) Myelofibrosis . Medical Education Podcast 2:11   Presentation and Risk Stratification of Myelofibrosis 0:36   Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma 2:02   Analyses from COMFORT trials of ruxolitinib for myelofibrosis 1:01   The role of interferon in PV 1:55   Recent updates on CELMoDs in multiple myeloma 2:07   Analysis of long-term exposure to momelotinib in the Phase III SIMPLFY myelofibrosis trials 1:38   CARTITUDE-1 final results: PFS of cilta-cel in patients with heavily pre-treated R/R myeloma 3:16   The importance of early intervention in young patients with MPNs & the role of interferon therapy 3:13   Therapies for patients who progress on JAK inhibitors: imetelstat, navtemadlin, selinexor & TP-3654